A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe symptoms linked to RSV and other respiratory viruses. Hospitalizations ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

RSV is causing thousands of infant deaths in India yearly, yet remains underdiagnosed. Experts stress the urgent need for ...

Reduction in 2024-2025 RSV-associated hospitalization rates seen among infants aged 0 to 7 months with maternal vaccination or nirsevimab.

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for respiratory syncytial virus–associated infections in young infants.

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu immunizations in 2025. The panel voted to expand RSV protection for infants ...

Medical experts in India are calling for urgent attention to Respiratory Syncytial Virus (RSV), a highly contagious but under-discussed cause of lower respiratory tract infections in infants ...

In this article, we identify the top 10 most impactful articles for pediatric hospital medicine in 2025, as presented at the Pediatric Update at SHM Converge 2025 in Las Vegas. Four publications are ...

Kennedy selected a new team of medical professionals and scientists who are highly qualified and dedicated to public health.